30
Participants
Start Date
October 31, 2010
Primary Completion Date
June 30, 2013
Study Completion Date
March 31, 2014
Adalimumab
Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
Department of Rheumatology U, Aarhus Hospital, Aarhus
Regional Hospital of Silkeborg, Silkeborg
Regional Hospital of Horsens, Department of Medicine, Horsens
Regional Hospital of Randers, Department of Medicine, Randers
Collaborators (2)
Abbott
INDUSTRY
Medtronic - MITG
INDUSTRY
Central Denmark Region
OTHER
Regionshospitalet Silkeborg
OTHER